Vaginal bromocriptine administration in patients with hyperprolactinemia

International Journal of Gynecology and Obstetrics

Volumn 65, Issue 1, 1999, Pages 77-78

  Carranza Lira, S ^a,b   Gonzalez Sanchez J L ^a   Martinez Chequer J C ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b NONE   (Mexico)

Author keywords

Bromocriptine; Colposcopy; PAP smear; Vaginal route

Indexed keywords

BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; FOLLITROPIN; LUTEINIZING HORMONE; PROLACTIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; HYPERPROLACTINEMIA; INTRAVAGINAL DRUG ADMINISTRATION; PAPANICOLAOU TEST; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL;

EID: 0345161641     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7292(98)00257-4     Document Type: Article

References (4)

1. Kinch RA. The use of bromocriptine in obstetrics and gynecology. Fertil Steril 1980;33:463-470.
2. Ginsburg J, Hardiman P, Thomas M. Vaginal bromocriptine, clinical and biochemical effects. Gynecol Endocrinol 1992;6:119-126.
3. Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes care 1996;19:667-670.
4. Obeid-Layon J, Carballar G, Espinosa de los Monteros A, Parra-Covarrubias A. Efectividad terapéutica de la bromocriptina (BEC) por vía vaginal en pacientes con hiperprolactinemia (Therapeutic efficacy of vaginal administration of bromocryptin in patients with hyperprolactinemia). Ginecol Obstet Mex 1993;61:254-260.